Critics question the FDA’s decision to approve OxyContin for children; AstraZeneca temporarily stops to lung-cancer trials; Sanders will oppose Califf’s nomination as FDA commissioner
Five things for pharma marketers to know: Thursday, September 17, 2015
New analysis says Paxil is not safe or effective for teens; some FDA reviewers voted against Addyi approval over side effects; HHS partners with AstraZeneca on antibiotic development
Five things for pharma marketers to know: Friday, August 21
Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe
Five things for pharma marketers to know: Friday, July 24
UnitedHealth looks for refunds when drugs don’t work; the European Medicines Agency recommends Sanofi’s and Regeneron’s PCSK9 inhibitor, Praluent, for approval; Biogen’s multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth
Five things for pharma marketers to know: Friday, July 17
Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker
Five things for pharma marketers to know: Wednesday, July 15
Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands
Five things for pharma marketers to know: Tuesday, July 14
The FDA approves AstraZeneca’s Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy’s launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices
Steady Leadership, Focus on Infrastructure Expected from the FDA’s “Acting” Head